2000
DOI: 10.1016/s0969-8051(00)00110-4
|View full text |Cite
|
Sign up to set email alerts
|

Radioligands for the study of brain 5-HT1A receptors in vivo–development of some new analogues of way

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
23
0

Year Published

2004
2004
2019
2019

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 47 publications
(24 citation statements)
references
References 28 publications
1
23
0
Order By: Relevance
“…We had successfully synthesized a ligand containing dithiocarbamate moiety for incorporating 99m Tctricarboxyl core. 99m Tc(CO) 3 -MPPDTF showed moderate brain uptake with good retention [12]. The specific binding of this radiotracer to 5-HT 1A receptor was also confirmed partially by blocking experiment in mice.…”
Section: -Htmentioning
confidence: 59%
See 2 more Smart Citations
“…We had successfully synthesized a ligand containing dithiocarbamate moiety for incorporating 99m Tctricarboxyl core. 99m Tc(CO) 3 -MPPDTF showed moderate brain uptake with good retention [12]. The specific binding of this radiotracer to 5-HT 1A receptor was also confirmed partially by blocking experiment in mice.…”
Section: -Htmentioning
confidence: 59%
“…The (2-methoxyphenyl)piperazine (MPP) moiety, residue of WAY 100635, which is known to have high affinity to the 5-HT 1A receptor, was selected as the prototype structure for the design of potential radiotracers [2,3]. Many 99m Tc labeled complexes carrying MPP moiety with high affinity for the 5-HT 1A receptor have been reported [4][5][6][7][8].…”
Section: -Htmentioning
confidence: 99%
See 1 more Smart Citation
“…Specific radioligands and single-photon emission computer tomography (SPECT) or positron emission tomography (PET) allow for a quantitative imaging of brain 5-HT 1A receptor distribution in living animals and humans. In the past few years, PET agents for imaging 5-HT 1A receptor have been studied extensively [1,[6][7][8][9][10][11][12][13][14] , such as 11 Clabeled N- (2-[4-(2-methoxyphenyl) -1-piperazinyl] ethyl-N- (2-pyridinyl) cyclohexanecarboxamide [ 11 C-WAY-100635] [6,13] , 4-(2′-methoxyphenyl)-1-[2′-(N-2′′-pyridinyl) -p-18 F-fluorobenzamido] ethylpiperazine [ 18 F-MPPF] [9,15] , 18 F-labeled trans-4-fluoro-N- (2-[4-(2-methoxyphenyl) piperazin-1-yl)ethyl]-N-(2-pyridyl)cyclohexanecarboxam ide [ 18 F-FC WAY]) [14] , and N-{2- [4-(2-methoxyphenyl) piperazinyl]ethyl}-N-(2-pyridyl)-N-(4-18 F-fluoro-methylcyclohexane)carboxamide ( 18 F-MEFWAY) [16] . Among those PET tracers, a fluoro-analogue of WAY 100635 ([ 18 F]p-MPPF) has been investigated extensively and received the most concerns due to its positive results obtained in animals and human beings [1,11,[17][18][19] .…”
Section: N-(2-(1-(4-(2-methoxyphenyl)piperazinyl)-ethyl))-n-(2-mentioning
confidence: 99%
“…Consequently, the search for alternative radioligands which can be prepared more easily while showing improved metabolic resistance is still a relevant issue. 4,5,[11][12][13][14][15] Several studies highlighted the tolerance of the WAY-100635 lead structure to replacement of the pyridinyl amide group by other substituents, including bulky metallic fragments, such as [ 19,20 These building blocks were functionalized with piperazinyl fragments, which were incorporated at the 5-position of the azole ring. 21 Some of the resulting functionalized complexes displayed excellent sub-nanomolar affinities for 5-HT 1A receptors, and their biodistribution is currently under evaluation.…”
Section: Introductionmentioning
confidence: 99%